RemeGen’s telitacicept produced a large proteinuria reduction in a prespecified interim analysis of its Phase 3 TELIGAN program in high-risk IgA nephropathy, according to results published in NEJM. In 318 adults, weekly subcutaneous telitacicept (240 mg) cut the 24-hour urinary protein-to-creatinine ratio by 58.9% at week 39 versus an 8.8% decline with placebo (relative difference −55.0%, P<0.001).